Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring

Launched by CENTRE OSCAR LAMBRET · Aug 12, 2022

Keywords

ClinConnect Summary

This clinical trial is looking to compare two different ways of monitoring patients who have recently been diagnosed with certain rare tumors. The goal is to see if patients are more likely to follow their follow-up care plan when it’s handled in person by a doctor at the hospital or remotely by a trained nurse over the phone. Participants will be adults aged 18 and older who have been diagnosed with specific conditions, such as Stage I testicular seminoma, gastrointestinal stromal tumors, or certain types of ovarian tumors, within the last year.

If you decide to participate, you will be randomly assigned to one of the two monitoring groups and will continue to receive care according to national guidelines. This trial is currently recruiting participants, so if you meet the eligibility criteria and are interested, you’ll need to give your consent to join. It’s also important to note that participants will need to have access to a telephone, as it will be necessary for the remote monitoring option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Positive diagnosis (anatomopathology) of tumor within 12 months
• • Patient 18 years of age or older
• * Patient with one of the following conditions:
• • 1. Desmoid fibromatosis of the abdominal wall operated on or under active surveillance
• • 2. Stage I testicular seminoma (whether or not treated with carboplatin AUC7)
• • 3. Stage I non-seminomatous germ cell tumor (with or without adjuvant BEP chemotherapy)
• • 4. Operated GIST with low risk of relapse
• • 5. Rare gynecological tumors (sex cord and stromal tumors; germ cell tumors of the ovary, clear cell adenocarcinoma, mucinous adenocarcinoma of the ovary, borderline tumors, small cell carcinoma, ovarian and uterine carcinosarcoma, low grade serous tumors), operated
• • 6. Low-grade glioma, operated
• • 7. Low-grade neuroendocrine tumor, treated by surgery alone
• • Patient who has given consent to participate in the study
• Exclusion Criteria:
• • Contraindication to imaging tests required for the surveillance plan
• • No telephone
• • Patient under guardianship or curatorship